Compare Citius Pharmaceuticals Inc (CTXR) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Southern Copper Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Southern Copper Corp trades at $209.14 (market cap $167.74B). The key difference: Southern Copper Corp is far larger — about 12315.7× Citius Pharmaceuticals Inc's market cap, and Southern Copper Corp pays a 2.21% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Southern Copper Corp for 61 Days on average.
| CTXR | SCCO | |
|---|---|---|
Market Cap | $13.62M | $167.74B |
Volume | 132,438 | 853,110 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $219.70 |
52-Week Low | $0.48 | $120.02 |
Typical Hold Time | 17 Days | 61 Days |
Enterprise Value | $3.79M | $169.03B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Southern Copper (SCCO) trades at $208.31, up 3.86% over the past day, but remains below the consensus price target of $167.67. The stock shows strong fundamentals with revenue rising to $13.42B in 2025 and net income reaching $4.33B, though valuation ratios like a P/E of 29.81 and P/S of 10.72 appear elevated. Recent earnings beats and a bullish long-term growth outlook from projects like the $10.2B Mexican pipeline contrast with a bearish technical signal and mixed analyst sentiment.
SCCO presents a cautious outlook due to high valuations and bearish technicals, but robust profitability and expansion projects offer growth potential. Key risks include reliance on copper prices and competitive pressures, while institutional activity shows divided interest. Investors should weigh strong cash flows against premium pricing before entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
